A big, deep dive into CTA and fractional flow reserve CT, and a sobering report on the new EVOQUE valve are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback and Correction

• CRAAFT HF https://clinicaltrials.gov/study/NCT06505798

II Imaging and Behavior Change

• SCOT HEART 1 https://www.nejm.org/doi/full/10.1056/NEJMoa1805971
• Five Reasons I Don't Believe an Imaging Test Improves Outcomes https://www.medscape.com/viewarticle/901204
• SCOT HEART 2 https://www.jacc.org/doi/10.1016/j.jcmg.2024.05.016

III. More on Imaging and CT FFR Symptoms Don’t Always Indicate the Severity of Coronary Artery Disease https://www.medscape.com/viewarticle/symptoms-dont-always-indicate-severity-coronary-artery-2025a1000ge6

• ADVANCE Registry Protocol https://www.journalofcardiovascularct.com/article/S1934-5925(16)30288-X/abstract

• Research Letter JACC CV Imaging  https://doi.org/10.1016/j.jcmg.2025.05.002
• ADVANCE Registry Paper 2018 https://doi.org/10.1093/eurheartj/ehy530
• Cook et al JAMA Card https://jamanetwork.com/journals/jamacardiology/fullarticle/2629072
• Low diagnostic yield Patel paper NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa0907272
• Venk Murthy thread https://x.com/venkmurthy/status/1033379922679660544

IV EVOQUE Real World Data

JACC has published a sobering research letter on the Transcatheter Tricuspid Valve Replacement called EVOQUE valve.

• Lupu et al JACC IV https://doi.org/10.1016/j.jcin.2025.03.019
• TRISCEND II https://www.nejm.org/doi/full/10.1056/NEJMoa2401918

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Listener feedback on cardiac sarcoidosis, SA node ablation, surgical AF ablation, chronic kidney disease protection, and recruiting for clinical trials are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338
• Nordenswan et al https://www.ahajournals.org/doi/full/10.1161/CIRCEP.117.006145#tab-contributors

II IST

• HR Case Reports https://doi.org/10.1016/j.hrcr.2025.05.017
• Lakkireddy et al https://doi.org/10.1016/j.hrthm.2021.07.010

III Survival After Surgical AF ablation during CABG

• McClure et al https://doi.org/10.1093/europace/eux336
• Schaffer et al https://doi.org/10.1016/j.athoracsur.2025.03.044

IV Finerenone with Empagliflozin in CKD and DM

• The Confidence Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2410659

V Recruiting for Important Trials and the Stature of EP as a Profession

Two UK Cardiology Trials Struggle to Recruit Patients

https://www.medscape.com/viewarticle/two-uk-cardiology-trials-struggle-recruit-patients-2025a1000ffs

• CRAFT HF https://clinicaltrials.gov/study/NCT06505798
• BRITISH https://doi.org/10.1016/j.ahj.2023.09.008
• PROFID https://profid-project.eu/profid-ehra-trial/

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Listener feedback on cardiac sarcoidosis, out-of-hospital cardiac arrest, less is more when it comes to post-stent antiplatelets, lipoprotein(a), and atrial fibrillation in HFpEF are discussed by John Mandrola, MD, in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• Mathijssen https://doi.org/10.1093/eurheartj/ehaf338
• Poyhonen https://doi.org/10.1161/CIRCEP.124.013239

II News in out of hospital cardiac arrest

• AHA Press Release https://newsroom.heart.org/news/nfl-safety-justin-reid-expands-cpr-education-for-youth-through-summer-program
• Chan et al https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.124.011799

III Post-Stent Antiplatelet

• 4D ACS trial https://eurointervention.pcronline.com/article/one-month-dual-antiplatelet-therapy-followed-by-prasugrel-monotherapy-at-a-reduced-dose-the-4d-acs-randomised-trial

IV Lp(a) and the new PREVENT equation for Predicting cardiac events

• Aug 02, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001429

• Bhatia et al https://jamanetwork.com/journals/jamacardiology/fullarticle/2835022

V AF in HFpEF

• Saksena et al https://doi.org/10.1093/europace/euad095

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Listener feedback, CRT vs CSP, important clues on the ECG, beta-blocker interruption after myocardial infarction, novel approaches to LDL-C lowering, and ICD decisions in cardiac sarcoidosis are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

II CRT vs CSP – CONSYST-CRT

• Trial JACC EP https://doi.org/10.1016/j.jacep.2025.03.024

III The Important QRS

• Kewcharoen et al https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013809

IV ABYSS Trial of BB Interruption after MI Continues to be Mis-interpreted

• ABYSS Main https://www.nejm.org/doi/full/10.1056/NEJMoa2404204

• ABYSS substudy https://doi.org/10.1093/eurheartj/ehaf170

• REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479

V Oral PCSK9i and the PURSUIT Trial

• Koren et al https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499

• Editorial https://doi.org/10.1016/j.jacc.2025.03.518

• Is Lifelong LDL-C Lowering Within Reach? The heart-1 Gene-Editing Trial https://www.medscape.com/viewarticle/998162

• Heart-1 Gene Therapy Trial Pauses Enrollment https://www.medscape.com/viewarticle/998162

• EHJ coverage VERVE https://academic.oup.com/ehjcvp/article/10/2/87/7455877

VI Cardiac Sarcoidosis and Risk of VT

• EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Listener feedback on sports “disqualification,” big digoxin news, Brugada syndrome, another positive finerenone study, and unblinded transcatheter trials are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

• JACC EP Paper https://www.jacc.org/doi/10.1016/j.jacep.2025.03.013

II Digoxin News

• DIGIT HF Baseline Characteristics paper https://doi.org/10.1002/ejhf.3679
• DIGIT HF Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC6607489/
• Dig trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801
• DECISION trial https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.3428
• Ziff et al BMJ meta-analysis https://www.bmj.com/content/351/bmj.h4451

III Brugada Syndrome

• Gomes et al https://doi.org/10.1093/europace/euaf091

IV Another Finerenone Substudy Published

• FINEARTS-HF trial substudy, Bhatt, A et al https://doi.org/10.1016/j.cardfail.2025.05.006
• FINEARTS HF Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
• TOPCAT https://www.nejm.org/doi/full/10.1056/NEJMoa1313731
• TOPCAT regional variation Circ paper https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255

V Another Opinion on Unblinded Transcatheter Intervention Trials

• Kaul https://eurointervention.pcronline.com/article/unblinded-trials-of-transcatheter-interventions-with-subjective-endpoints-what-are-the-implications

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

The BedMed trial of nighttime BP meds, SURMOUNT-5, Troponin URL, gene tests in patients with no disease, and guideline-directed medical therapy for HF are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Timing of BP Meds – The BedMed RCT

• MAPEC https://doi.org/10.3109/07420528.2010.510230
• Hygia https://doi.org/10.1093/eurheartj/ehz754
• Turgeon et al https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.16501
• TIME trial https://doi.org/10.1016/S0140-6736(22)01786-X
• BedMed https://jamanetwork.com/journals/jama/fullarticle/2833860
• Time Antihypertensives Taken Doesn't Matter: New Trials https://www.medscape.com/viewarticle/time-antihypertensives-taken-doesnt-matter-new-trials-2024a1000g3z
• Timing of BP Dosing Doesn't Matter: BedMed and BedMed-Frail https://www.medscape.com/viewarticle/timing-blood-pressure-dosing-doesnt-matter-again-bedmed-and-2024a1000fz2
• Timing of Blood Pressure Meds Doesn’t Affect Outcomes: BedMed in Print https://www.medscape.com/viewarticle/timing-blood-pressure-meds-doesnt-affect-outcomes-bedmed-2025a1000cdm

II Tirzepatide vs Semaglutide

• SURMOUNT 5 https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

III Age-specific Troponins

• Coyle and McEvoy https://doi.org/10.1093/eurheartj/ehaf308
• Mandrola/Foy JAMA-IM https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967

IV Return to Play for Gene Positive Phenotype Negative athletes

• Martinez et al https://doi.org/10.1016/j.jacep.2025.03.013

V Rapid Titration of GDMT in HF

STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698

• JACC-HF Substudy https://doi.org/10.1016/j.jchf.2025.02.020
• STRONG HF https://doi.org/10.1016/S0140-6736(22)02076-1
• AVID https://www.nejm.org/doi/full/10.1056/NEJMoa013474
• EAST https://www.nejm.org/doi/full/10.1056/NEJMoa013474

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I The KETO-CTA Study

• JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
• Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009

II Subclinical AF – Anticoagulate or Not?

Anticoagulation in Subclinical AF May Offer Little Benefit

https://www.medscape.com/viewarticle/anticoagulation-subclinical-af-may-offer-little-benefit-2025a1000b31

Treat AFib ‘Diagnosed’ by Smartwatch

https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp

• JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
• NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
• ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
• McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
• Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
• Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
• American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/

III GLP1a for Treatment of Fatty Liver Disease

• ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258

Features

• CABG Still Superior to Stents Despite FAME 3 Endpoint Swap

https://www.medscape.com/viewarticle/cabg-still-superior-stents-despite-fame-3-endpoint-swap-2025a1000ao5

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

The FDA approval of TAVR for asymptomatic AS, digital health, subcutaneous vs transvenous ICD, and cryptogenic stroke in young adults are discussed by John Mandrola, MD.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I  FDA announces approval for TAVR in pts with asymptomatic AS

• Edwards Press Release https://www.edwards.com/newsroom/news/2025-05-01-edwards-tavr-receives-fda-approval-for-patients-with-asymptomatic-severe-aortic-stenosis
• Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis (EARLY TAVR) https://www.nejm.org/doi/full/10.1056/NEJMoa2405880
• EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
• Asymptomatic Aortic Stenosis: 'Time to Act' or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9

II PPG that Can Distinguish source of Tachycardia

• Machine-learning guided differentiation between photoplethysmography waveforms of supraventricular and ventricular origin https://doi.org/10.1016/j.cmpb.2025.108798

III PRAETORIAN -XL trial

• Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074576
• Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN trial) https://www.nejm.org/doi/full/10.1056/NEJMoa1915932
• Subcutaneous or Transvenous Defibrillator Therapy Letter to Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917
• The PRAETORIAN Trial: Guarded Approach to Subcutaneous ICD Best https://www.medscape.com/viewarticle/937156

IV Stroke in Young People

• Burden of Modifiable Risk Factors in Young-Onset Cryptogenic Ischemic Stroke by High-Risk Patent Foramen Ovale https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.049855
• Migraine: A Key Factor in Young Adults With Unexplained Stroke https://www.medscape.com/viewarticle/migraine-key-factor-young-adults-unexplained-stroke-2025a10009jj
• U.S. stroke rate declining in adults 75 and older, yet rising in adults 49 and younger ASA statement https://newsroom.heart.org/news/u-s-stroke-rate-declining-in-adults-75-and-older-yet-rising-in-adults-49-and-younger
• Increasing stroke in the young https://doi.org/10.1016/j.ajpc.2020.100085

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

AI and ECGs, novel ways to treat hypertension, combined lipid-lowering therapy after myocardial infarction, PFA and silent stroke, a move toward accountability in AF ablation, and pacing issues in TTVR are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Help with ECGs in the ED

AI Shows Promise for Rapid NSTEMI Diagnosis

https://www.medscape.com/viewarticle/ai-shows-promise-rapid-nstemi-diagnosis-2025a10009pw

• Buscher et al https://doi.org/10.1093/eurheartj/ehaf254

II A Novel way to Treat HTN

A Pacemaker to Control BP Gets FDA Breakthrough Designation

https://www.medscape.com/viewarticle/pacemaker-control-bp-gets-fda-breakthrough-designation-2025a10009t3

• JAHA paper https://www.ahajournals.org/doi/10.1161/JAHA.120.020492
• Backbeat https://clinicaltrials.gov/study/NCT06059638

III Type of PFA may matter for Silent Cerebral Lesions

• Paper https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013719

IV Accountability coming to US AF ablation

• Heart Rhythm Society Releases a Document on Establishing Centers of Excellence for AF ablation -- Press Release https://www.hrsonline.org/news/new-white-paper-on-atrial-fibrillation-centers-of-excellence/

V Pacing in Patients with Undergoing Transcatheter Tricuspid Valve Replacement

• Paper https://doi.org/10.1016/j.hrthm.2025.02.004

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I FAME 3 at Five Years

Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4

• Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299
• Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
• 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057

II TAVR in Low-Risk Patients at 5 years

5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients

https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl

• EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004
• EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428
• PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
• NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606

III The Matter of Pacemakers After TAVI

• JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028
• Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals
•  

IV Mavacamten Looks to Have Specific Indications

• EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link
• VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050
• BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/

FINAL THOUGHTS

• PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]